Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049554 | 0.85 | MCL1 (0.44) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5117972 | 0.81 | PPARG (0.44) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5117910 | 0.80 | LMNA (0.39) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL4048516 | 0.80 | PPARG (0.46) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL3747639 | 0.79 | KDM4E (0.60) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5125532 | 0.78 | PPARG (0.48) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5124452 | 0.78 | PPARG (0.40) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5872500 | 0.78 | GFER (0.40) | GFERMCL1KDM4EALDH1A1HPGD | |
| SCHEMBL5125257 | 0.77 | SMN1; SMN2 (0.41) | GFERMCL1KDM4EHPGDHSD17B10 | |
| SCHEMBL5111493 | 0.76 | BRAF (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | claimed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| US-7078419-B2 | N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235017-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1R1 | GFER 2265/4885MCL1 1081/4885KDM4E 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.